EyeCon 2026 Banner

Lynda Charters

Articles by Lynda Charters

In a presentation at the American Society of Cataract and Refractive Surgery’s 2022 annual meeting, Marjan Farid, MD, ABO, and Preeya K. Gupta, MD, offered details of clinical trials for CSF-1 ophthalmic solution, a presbyopia eye drop candidate. Results showed that nearly half of the participants treated with CSF-1 achieved a 3-line or more increase in the distance-corrected near visual acuity an hour after drop instillation on day 15.

According to an e-poster presented by Jagadesh C. Reddy, MD, and Harini Indusekar, BScOptom, at the American Society of Cataract and Refractive Surgery’s 2022 annual meeting in Washington, D.C., patients who have pre-existing DR are less likely to achieve Snellen 20/40 or better vison after cataract surgery compared with the patients with diabetes but without DR.

Blake K. Williamson, MD, MPH, MS, and coauthor Urvi Patel, BSc, presented an e-poster at the American Society of Cataract and Refractive Surgery’s 2022 annual meeting in Washington, D.C., on the efficacy of a combination eye drop comprised of an antibiotic, anti-inflammatory and lubricant as part of a postoperative treatment regimen following cataract surgery.

Luis Acaba-Berrocal, MD, of the Illinois Eye and Ear Infirmary in Chicago, worked with a group of colleagues to conduct a multicenter, retrospective, consecutive study of infants with ROP who had been treated with intravitreal anti-VEGF injections between 2008 and 2020 in light of the dearth of real-world data on the topic.

Demodex blepharitis is a virtual epidemic in the US; an estimated 20 million people have blepharitis, and of that population, almost half have Demodex. A new therapeutic is the sole treatment option that targets the disease.